Results 131 to 140 of about 5,163 (181)

Optimizing phage-antibiotic combinations: impact of administration order against daptomycin non-susceptible (DNS) MRSA clinical isolates. [PDF]

Antimicrob Agents Chemother
Bleick CR, Van Helden SR, Berti AD, Richa R, Lehman SM, Bayer AS, Rybak MJ.   +6 more
europepmc   +1 more source

Penicillin-Binding Protein-4 (PBP4) of <i>Staphylococcus aureus</i> and Its Role in β-Lactam Resistance: An Update. [PDF]

Microorganisms
Satishkumar N, Chatterjee SS.
europepmc   +1 more source

Reply to White and Siegrist, "Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges". [PDF]

Antimicrob Agents Chemother
Arias CA, Tran TT, Kinsella P, Howden BP, Miller WR.   +4 more
europepmc   +1 more source

Intravenous Ceftaroline in Extremely Premature Neonates With Coagulase-Negative Staphylococci Septicemia: A Report of 2 Cases. [PDF]

J Pediatr Pharmacol Ther
Assfour SS, AlMoghaileth FA, Abdelrahim A, Hassouneh AK, Salem SO, Assfour RS, Khalil TM, Al-Mouqdad MM.   +7 more
europepmc   +1 more source

Off-label use of ceftaroline fosamil: A systematic review [PDF]

International Journal of Antimicrobial Agents, 2019
Ceftaroline fosamil is a fifth-generation cephalosporin and the unique with anti-MRSA activity. It has been approved by EMA and FDA for the treatment of adults and children with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and ...
Daniele Pastori, Arianna Pani, Francesco Scaglione   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

CEFTAROLINE

Infectious Diseases in Clinical Practice, 2014
AbstractCephalosporins are widely used antibiotics throughout the world. However, with the availability of multiple agents in this class with varying spectrum of activity and clinical use, selecting the most appropriate cephalosporin can become convoluted.
Steven W. Johnson, D. Byron May
openaire   +2 more sources